|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||
|
Mayo Clinic, Jacksonville, FL
PURPOSE: Previous studies have reported increased mortality among obese lung transplant (LT) recipients. This retrospective study evaluated the short and long term outcomes of obese (Body Mass Index or BMI equal or >30) lung transplant recipients, compared to non-obese (BMI<30) patients.
METHODS: Retrospective collection of data from the Mayo Clinic Lung Transplant Database among 63 patients receiving lung transplants from June 2001 to June 2004 at the Mayo Clinic. Demographic data, height and weight at time of transplant, BMI, clinical outcomes and survival rates were collected and compared among the 2 groups.
RESULTS: Out of 63 LT recipients, 48 (76%) were Non-Obese (weight= 67 +-15 kg and BMI= 24+-4), and 15 (14%) were Obese (weight= 92.4+-9 and BMI 31.4+-1). Clinical outcomes during lung transplant were as follows: For Non-Obese recipients, the ICU stay was 9+-11 days. The Lenght of stay (LOS) was 24+-19 days. Obese patients required an ICU stay of 8+-9 days. The LOS was 24+-18 days (Not statistically significant) The survival at 1 month, 6 months and 12 months were as follows. Non-Obese: 98%, 84% and 76% (mean survival 20+-12 months). Obese recipients: 100%, 100% and 100% (mean survival 24+-10 months up to the current date).
CONCLUSION: In our experience, 15 patients who were obese at the time of transplant (BMI ranging from 30 to 35.6) had as good or better immediate post-op course after lung transplantation compared to Non-Obese patients (BMI ranging from 18 to 29.7). Survival rates for obese lung transplant recipients up to one year after transplant were as good or better than non-obese patients.
CLINICAL IMPLICATIONS: The assumption that a BMI > 30 represents likelihood of increased morbidity or mortality among lung transplant recipients may not be necessarily true. Larger studies with longer follow up may find expanded criteria for potential lung transplant recipients with BMI as high as 35 if these preliminary results are confirmed by larger clinical trials.
DISCLOSURE: Debra Boswell, None.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |